Latest News
Circassia’s Hay Fever Treatment Improves Patients’ Allergy Symptoms in Phase II Clinical Trial
Treatment Progresses into Final Phase II Clinical Study
27 September 2011
Circassia's Rapid Four-Dose ToleroMune Treatment Maintains Significant Reduction in Allergy Symptoms During 12-Month Follow-up
Results Presented at Plenary Symposium of European Academy of Allergy and Clinical Immunology Congress
13 June 2011
Circassia Completes £60 Million ($98 Million) Fundraising For Final-Stage Development of Lead Allergy Products
19 April 2011
Circassia Acquires Worldwide Rights to Novel Psoriasis and Atopic Dermatitis Treatment from Airmid Inc
09 February 2011
Circassia ToleroMune T-cell Vaccine Achieves Significant Reduction in Allergy Symptoms in Key Phase II Clinical Study
Study Provides Proof-of-Concept for Commercial Formulation and Final Stage of Development
01 February 2011
Did you know?
The average bed could be home to up to 1.5 million house dust mites